NO314933B1 - Vannfrie krystaller, medikament omfattende slike samt fremgangsmåte for fremstilling av vannfrie krystaller - Google Patents
Vannfrie krystaller, medikament omfattende slike samt fremgangsmåte for fremstilling av vannfrie krystaller Download PDFInfo
- Publication number
- NO314933B1 NO314933B1 NO19974369A NO974369A NO314933B1 NO 314933 B1 NO314933 B1 NO 314933B1 NO 19974369 A NO19974369 A NO 19974369A NO 974369 A NO974369 A NO 974369A NO 314933 B1 NO314933 B1 NO 314933B1
- Authority
- NO
- Norway
- Prior art keywords
- crystals
- compound
- anhydrous
- drying
- temperature
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 117
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 238000001035 drying Methods 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- 230000004584 weight gain Effects 0.000 claims description 10
- 235000019786 weight gain Nutrition 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 abstract description 3
- -1 2-oxo-1-pyrrolidinyl group Chemical group 0.000 abstract description 2
- 239000002245 particle Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000002915 carbonyl group Chemical class [*:2]C([*:1])=O 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical class [H]O* 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6423495 | 1995-03-23 | ||
| JP9478295 | 1995-04-20 | ||
| PCT/JP1996/000485 WO1996029308A1 (fr) | 1995-03-23 | 1996-03-01 | Cristaux anhydres |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO974369D0 NO974369D0 (no) | 1997-09-22 |
| NO974369L NO974369L (no) | 1997-11-24 |
| NO314933B1 true NO314933B1 (no) | 2003-06-16 |
Family
ID=26405355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19974369A NO314933B1 (no) | 1995-03-23 | 1997-09-22 | Vannfrie krystaller, medikament omfattende slike samt fremgangsmåte for fremstilling av vannfrie krystaller |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6169108B1 (zh) |
| EP (1) | EP0819676B1 (zh) |
| KR (1) | KR100402554B1 (zh) |
| CN (1) | CN1084734C (zh) |
| AT (1) | ATE224873T1 (zh) |
| AU (1) | AU4843696A (zh) |
| CA (1) | CA2215846A1 (zh) |
| DE (1) | DE69623943T2 (zh) |
| DK (1) | DK0819676T3 (zh) |
| EA (1) | EA000301B1 (zh) |
| ES (1) | ES2184852T3 (zh) |
| HK (1) | HK1008991A1 (zh) |
| NO (1) | NO314933B1 (zh) |
| PT (1) | PT819676E (zh) |
| TW (1) | TW430653B (zh) |
| WO (1) | WO1996029308A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| CN105512207B (zh) * | 2015-11-27 | 2019-04-09 | 上海携程商务有限公司 | 争抢式的数据复制方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2923975A1 (de) * | 1979-06-13 | 1980-12-18 | Nattermann A & Cie | Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel |
| IT1141287B (it) * | 1979-06-13 | 1986-10-01 | Nattermann A & Cie | Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono |
| US5461157A (en) * | 1992-06-19 | 1995-10-24 | Daiichi Pharmaceutical Co., Ltd. | Process for preparing pyrrolidinylacetamide derivatives |
| NO179903C (no) * | 1992-06-19 | 1997-01-08 | Daiichi Seiyaku Co | Fremgangsmåte for fremstilling av et halogenacetamidderivat samt et pyrrolidinylacetamidderivat |
-
1996
- 1996-03-01 ES ES96904290T patent/ES2184852T3/es not_active Expired - Lifetime
- 1996-03-01 EA EA199700259A patent/EA000301B1/ru not_active IP Right Cessation
- 1996-03-01 PT PT96904290T patent/PT819676E/pt unknown
- 1996-03-01 KR KR1019970706644A patent/KR100402554B1/ko not_active IP Right Cessation
- 1996-03-01 EP EP96904290A patent/EP0819676B1/en not_active Expired - Lifetime
- 1996-03-01 AT AT96904290T patent/ATE224873T1/de not_active IP Right Cessation
- 1996-03-01 DK DK96904290T patent/DK0819676T3/da active
- 1996-03-01 US US08/913,615 patent/US6169108B1/en not_active Expired - Fee Related
- 1996-03-01 AU AU48436/96A patent/AU4843696A/en not_active Abandoned
- 1996-03-01 TW TW085102463A patent/TW430653B/zh active
- 1996-03-01 WO PCT/JP1996/000485 patent/WO1996029308A1/ja active IP Right Grant
- 1996-03-01 CA CA002215846A patent/CA2215846A1/en not_active Abandoned
- 1996-03-01 CN CN96192781A patent/CN1084734C/zh not_active Expired - Fee Related
- 1996-03-01 DE DE69623943T patent/DE69623943T2/de not_active Expired - Fee Related
-
1997
- 1997-09-22 NO NO19974369A patent/NO314933B1/no not_active IP Right Cessation
-
1998
- 1998-08-10 HK HK98109795A patent/HK1008991A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US6169108B1 (en) | 2001-01-02 |
| DK0819676T3 (da) | 2003-01-27 |
| TW430653B (en) | 2001-04-21 |
| KR100402554B1 (ko) | 2005-09-02 |
| HK1008991A1 (en) | 1999-07-30 |
| CA2215846A1 (en) | 1996-09-26 |
| ES2184852T3 (es) | 2003-04-16 |
| ATE224873T1 (de) | 2002-10-15 |
| CN1084734C (zh) | 2002-05-15 |
| AU4843696A (en) | 1996-10-08 |
| DE69623943T2 (de) | 2003-08-07 |
| EA199700259A1 (ru) | 1998-02-26 |
| EP0819676A4 (en) | 1998-07-08 |
| WO1996029308A1 (fr) | 1996-09-26 |
| NO974369L (no) | 1997-11-24 |
| DE69623943D1 (de) | 2002-10-31 |
| EP0819676A1 (en) | 1998-01-21 |
| PT819676E (pt) | 2003-01-31 |
| KR19980703240A (ko) | 1998-10-15 |
| EA000301B1 (ru) | 1999-04-29 |
| NO974369D0 (no) | 1997-09-22 |
| CN1179149A (zh) | 1998-04-15 |
| EP0819676B1 (en) | 2002-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2198169C2 (ru) | Полиморфные формы 2-(3-циан-4-изобутилоксифенил)-4-метил-5-тиазолкарбоновой кислоты и способы их получения | |
| DE69115229T2 (de) | Arzneimittel. | |
| HU229206B1 (en) | Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof | |
| NO326965B1 (no) | a-form eller β-form-krystall av acetanilid-derivat og farmasoytisk preparat | |
| SK403591A3 (en) | 2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents | |
| GB2336364A (en) | Paroxetine methanesulfonate | |
| RU2134690C1 (ru) | 5-ацетамидо-2,3,4,5-тетрадеокси-4-гуанидино-d-глицеро-d-галакто-нон-2- енопиранозоновая кислота в кристаллической форме, способы получения, фармацевтическая композиция и способ ее получения | |
| NO314933B1 (no) | Vannfrie krystaller, medikament omfattende slike samt fremgangsmåte for fremstilling av vannfrie krystaller | |
| US3687932A (en) | Crystalline cytidine-5{40 -diphosphate choline monohydrate and production thereof | |
| EP0944612B1 (en) | N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate | |
| AU3095600A (en) | New pharmaceutical formulation | |
| NO179575B (no) | Farmasöytisk preparat inneholdende en fysikalsk form av forbindelsen N-[4-[5-(cyklopentyloksykarbonyl)amino-1-metylindol-3-ylmetyl-3-metoksybenzoylÅ-2-metylbenzensulfonamid | |
| HU220769B1 (hu) | N-[ 4-(5-/Ciklopentil-oxi-karbonil-amino/-l-metil-indol-3-il-metil)-3-metoxi-benzoil]-2-metil-benzolszulfonamid új fizikai módosulata és eljárás annak előállítására | |
| MXPA99005427A (en) | N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |